Antibody Drug Conjugates Market Report 2026

The antibody drug conjugates market size has grown exponentially in recent years. It will grow from $16.53 billion in 2025 to $20.28 billion in 2026 at a compound annual growth rate (CAGR) of 22.7%. The growth in the historic period can be attributed to increasing prevalence of cancer, advances in monoclonal antibody technology, rising adoption of targeted therapies, growth in clinical trials for oncology drugs, supportive regulatory frameworks.

The antibody drug conjugates market size is expected to see exponential growth in the next few years. It will grow to $46.95 billion in 2030 at a compound annual growth rate (CAGR) of 23.3%. The growth in the forecast period can be attributed to rising demand for personalized medicine, development of novel ADCs with improved safety profiles, integration of AI for drug discovery, expansion in emerging markets, partnerships between biotech and pharmaceutical companies. Major trends in the forecast period include targeted drug delivery optimization, novel linker and payload development, combination therapies with immunotherapy, expansion of oncology indications, personalized cancer treatment strategies.

The increasing number of clinical trial studies is expected to drive the growth of the antibody-drug conjugates (ADC) market. Clinical trials are research studies in which volunteers test new treatments, interventions, or diagnostic approaches to prevent, detect, or manage diseases. ADCs have emerged as a key class of targeted anti-cancer therapies, with a growing number of ADCs undergoing clinical evaluation for both hematologic cancers and solid tumors. For example, in December 2024, the Association of the British Pharmaceutical Industry (ABPI), a UK-based trade association, reported that industry-sponsored clinical trials in the UK increased from 411 in 2022 to 426 in 2023. This rising clinical trial activity highlights expanding research and innovation in ADC development, supporting market growth.

Major companies in the ADC market are introducing innovative production technologies, such as single-use reactors designed specifically for ADC manufacturing. These reactors enable faster, flexible, and contamination-free production by eliminating the need for batch cleaning and sterilization. For instance, in September 2024, Merck & Co., Inc., a US-based pharmaceutical company, launched the Mobius ADC Reactor. Using Ultimus Film technology, this system enhances bag durability and leak resistance, improving production efficiency by 70% while reducing contamination risks and labor requirements.

In December 2023, Pfizer Inc., a US-based pharmaceutical company, acquired Seagen for $43 billion. This acquisition strengthens Pfizer’s oncology portfolio and accelerates the development of next-generation ADC therapies. Seagen is a US-based biotechnology company specializing in discovering, developing, and commercializing transformative cancer medicines, including a leading ADC portfolio.

Major companies operating in the antibody drug conjugates market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Millennium Pharmaceuticals Inc., Gilead Sciences Inc., Daiichi Sankyo Company Limited, Sorrento Therapeutics Inc., Astellas Pharma Inc., Seagen Inc., Synthon BV, Genentech Inc., ImmunoGen Inc., Nordic Nanovector ASA, ADC Therapeutics SA, Immunomedics Inc., Mersana Therapeutics Inc., Heidelberg Pharma AG, Celldex Therapeutics Inc., Oxford BioTherapeutics, Concortis Biotherapeutics Corp., Antikor BioPharma Ltd., Eisai Co. Ltd., Merck KGaA.

North America was the largest region in the antibody-drug conjugates (ADCs) market in 2025. The Middle East is expected to be the fastest-growing region in the global antibody drug conjugates market share during the forecast period. The regions covered in the antibody drug conjugates market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the antibody drug conjugates market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the antibody-drug conjugates market by increasing the cost of imported raw materials, including monoclonal antibodies, linkers, and cytotoxic drugs, which are critical for manufacturing. The most affected segments include high-end ADC drugs and immunogen technologies, particularly in North America, Europe, and Asia-Pacific regions like China and India. While tariffs have raised production costs, they have also encouraged local manufacturing initiatives and investment in domestic supply chains, potentially reducing dependence on imports and fostering innovation in ADC development.

The antibody drug conjugates market research report is one of a series of new reports that provides antibody drug conjugates market statistics, including antibody drug conjugates industry global market size, regional shares, competitors with a antibody drug conjugates market share, detailed antibody drug conjugates market segments, market trends and opportunities, and any further data you may need to thrive in the antibody drug conjugates industry. This antibody drug conjugates market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Antibody-drug conjugates (ADCs) are medications designed to deliver chemotherapy directly to cancer cells. They consist of a cytotoxic drug linked to a monoclonal antibody that binds to a specific target on cancer cells. Once the ADC attaches to its target, the cytotoxic agent is released into the cancer cell.

The main components of ADCs include monoclonal antibodies, linkers, drugs or toxins, and others. Monoclonal antibodies are produced by cloning a single white blood cell, with each subsequent antibody derived from the same parent cell. Key products include Adcetris, Kadcyla, and others, utilizing technologies such as immunogen technology, Seattle Genetics technology, and Immunomedics technology. ADCs are used to treat blood cancers, breast cancer, ovarian cancer, lung cancer, brain tumors, and more, and are administered in hospitals, clinics, and other healthcare settings.

The antibody-drug conjugates (ADCs) market consists of sales of enfortumab vedotin, sacituzumab govitecan, trastuzumab emtansine, and trastuzumab deruxtecan. Values in this market are factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.